MaxCyte, Inc. Director Dealings and Issue of Equity (6562P)

TIDMMXCT TIDMTTM

RNS Number : 6562P

MaxCyte, Inc.

19 February 2021

MaxCyte, Inc.

("MaxCyte" or the "Company")

Director Dealings and Issue of Equity

Total Voting Rights

Gaithersburg, Maryland - 19 February 2021: MaxCyte (LSE: MXCT, MXCL, MXCN), the global cell-based medicines and life sciences company, announces that Will Brooke, Non-Executive Director of the Company, has exercised options over 40,900 shares of common stock, $0.01 par, of the Company ("Common Stock") ("Exercise"). The 40,900 new shares of Common Stock issued pursuant to the Exercise ("New Common Stock") have been sold by Mr Brooke at a price of 1015 pence per Common Stock ("Sale").

Following the Exercise and Sale, Mr Brooke's holding of Common Stock remains unchanged at a total of 50,302 Common Stock, representing 0.1% of the issued share capital of the Company. Mr Brooke holds a further 128,500 options over Common Stock.

Total voting rights

The new Common Stock will be allocated out of the common stock the subject of the block listing announced on 2 May 2017. The New Common Stock will rank pari passu with the existing shares of common stock of the Company. The total issued stock capital of the Company following the issue of the New Common Stock and following the recent issue of an additional 597,877 new Common Stock to non-PDMRs in satisfaction of the exercise of share options, is 84,555,946 shares of common stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 74,325,857 ; the number of restricted shares of Common Stock trading under the symbol 'MXCL' is 9,900,089 a nd the number of restricted shares of Common Stock trading under the symbol 'MXCN' will be 330,000.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 
 1    Details of the person discharging managerial responsibilities/person 
       closely associated 
 a)   Name                             Will Brooke 
     ===============================  =========================================== 
 2    Reason for the notification 
     ============================================================================ 
 a)   Position/status                  Non Executive Director 
     ===============================  =========================================== 
 b)   Initial notification/Amendment   Initial notification 
     ===============================  =========================================== 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ============================================================================ 
 a)   Name                             MaxCyte, Inc. 
     ===============================  =========================================== 
 b)   LEI                              54930053YHXULRFCU991 
     ===============================  =========================================== 
 4    Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ============================================================================ 
 a)   Description of                   Exercise of options and Sale of Common 
       the financial                    Stock 
       instrument, type 
       of instrument 
     ===============================  =========================================== 
 b)   Identification                   US57777K1060 
       Code 
     ===============================  =========================================== 
 c)   Nature of the                    Exercise of options and Sale of Common 
       transaction                      Stock by PDMR 
     ===============================  =========================================== 
 d)   Price(s) and volume(s)           Price(s)          Volume(s) 
     ===============================  =================  ======================== 
                                            N/A          40,900 (option exercise) 
                                             1015 pence   40,900 (sale of common 
                                                          stock) 
     ===============================  =================  ======================== 
 e)   Aggregated information           N/A 
       - Aggregated volume              N/A 
       - Price                          N/A 
     ===============================  =========================================== 
 f)   Date of the transaction          18 February 2021 
     ===============================  =========================================== 
 g)   Place of the transaction         London Stock Exchange, AIM Market (XLON) 
     ===============================  =========================================== 
 

For further information, please contact:

 
 
  MaxCyte Inc. 
    Doug Doerfler, Chief Executive Officer 
    Ron Holtz, Chief Accounting Officer       [phone] 
 
    Nominated Adviser and Joint Corporate 
    Broker 
    Panmure Gordon 
    Emma Earl 
    Freddy Crossley 
    Corporate Broking 
    Rupert Dearden                             [phone] 
 
    Joint Corporate Broker 
    Numis Securities Limited 
    James Black 
    Duncan Monteith                            [phone] 
   Joint Corporate Broker 
 
    Stifel Nicolaus Europe Limited 
    Healthcare Investment Banking 
    Nicholas Moore / Ben Maddison / 
    Samira Essebiyea 
    Corporate Broking 
    Nick Adams                                [phone] 
 

About MaxCyte

MaxCyte is a world-leading provider of cell-engineering enabling technology and is responsible for helping to bring next-generation cell and gene-editing therapies to life. The Company's technology is deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 140 cell therapy programmes, with more than 100 licensed for clinical use, and the Company has now entered into twelve clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL, MXCN) and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHTPMBTMTBBTBB

(END) Dow Jones Newswires

February 19, 2021 02:00 ET (07:00 GMT)